0      0

2020 Annual Meeting


AM20-38 - AM20-38: The Thin Line Between Advancement or Exploitation…the Role of the “Super Donor” in Allogeneic Cell Therapy


Oct 5, 2020 11:15am ‐ Oct 5, 2020 12:15pm


Credits: None available.

Standard: $25.00
Members: $20.00

Description

Discover why reliance on a small subset of “super donors” could introduce risk and ignite ethical considerations for cell and gene therapy companies seeking sustainable growth and scalability.

Learning Objectives:
  • Describe how known and unknown inherent differences in human beings and populations can impact starting material
  • Describe how access to a large pool of diverse donors is essential for current and future needs
  • Discover how the use/overuse of “super donors” involves not only technical, regulatory and medical issues, but also ethical and legal issues
  • Discuss strategic solutions for sustainable cell and gene therapy development and growth

Speaker(s):

Credits Available


AM20-38: The Thin Line Between Advancement or Exploitation…the Role of the “Super Donor” in Allogeneic Cell Therapy Evaluation

You must be logged in and own this session in order to post comments.

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content